Parabilis Medicines, Inc.
PBLSNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $706.52M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $22.66$42.49
- Volume (live)
- -
- Avg. volume (3M)
- 1.32M
Parabilis Medicines (PBLS) Stock Price & Financial Analysis
Parabilis Medicines Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $23.96 - $26.74 |
|---|---|
| 52-Week High | $42.49 |
| 52-Week Low | $22.66 |
| Open | $26.74 |
| Volume (last close) | 1.82M |
| Average Volume (3M) | 1.32M |
| 50-Day MA | $34.72 |
|---|
| Market Cap | 706.52M |
|---|---|
| Shares Outstanding | 28.91M |
| Price to Book (P/B) | 0.67 |
| EV/EBITDA | 1.58 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Parabilis Medicines at a Glance
As of the Oct 23, 2026 close, Parabilis Medicines (PBLS) has a market capitalization of $706.52M.
As of its latest reported balance sheet, it holds $1.09B in cash and securities against $39.25M of debt, a net cash position of $1.05B.
Parabilis Medicines does not currently pay a dividend.
At $24.44 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $22.66 to $42.48.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $41.75, 70.8% above the Oct 23, 2026 close.
Frequently Asked Questions About Parabilis Medicines
What is the current stock price for PBLS?
As of the Oct 23, 2026 close, PBLS stock trades at $24.44. The 52-week range is $22.66–$42.49, with a day range of $23.96–$26.74.
What is the P/E ratio for PBLS?
The P/E ratio (Price-to-Earnings) for PBLS is shown in the Key Statistics section. This valuation metric helps compare Parabilis Medicines, Inc. to industry peers.
Does PBLS pay dividends?
Parabilis Medicines does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for PBLS?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for PBLS is Buy. The average 12-month price target is $41.75, a 70.8% upside from the Oct 23, 2026 close of $24.44.
What is the market cap of PBLS?
As of the Oct 23, 2026 close, Parabilis Medicines's market capitalization is $706.5M, classifying it as a small-cap company. Parabilis Medicines operates in the Healthcare sector within the Biotechnology industry.